Table of contents


On 17 January 2018, orphan designation (EU/3/17/1965) was granted by the European Commission to Duchenne UK, United Kingdom, for metformin and L-citrulline for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
Metformin and L-citrulline
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
Orphan decision number

Sponsor's contact details

Duchenne UK
11 Bedford Road
London W4 1JD
United Kingdom
Tel. +44 (0)7929 623123

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating